Olezarsen for hyperlipoproteinemia type i

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Jul 2026: Trial registered, NCT07727538
  2. 31 Jul 2026: Trial started, NCT07727538

The trials

NCT07727538: A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

State
Under way
Phase
Phase 3
People
12 planned
Started
31 Jul 2026
Primary completion
Aug 2030
Arms
Cohort 1, Cohort 2
Results
None posted
  1. 27 Jul 2026: Trial registered
  2. 31 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.